# Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

> **NCT05032183** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent T Acute Lymphoblastic Leukemia
- Refractory B Acute Lymphoblastic Leukemia
- Refractory Lymphoblastic Lymphoma
- Refractory T Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **BIOLOGICAL:** Filgrastim-sndz
- **DRUG:** Leucovorin
- **DRUG:** Mercaptopurine
- **DRUG:** Mesna
- **DRUG:** Methotrexate
- **BIOLOGICAL:** Pegfilgrastim
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Tagraxofusp-erzs
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT05032183
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-17
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The study was terminated early due to slow enrollment.
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05032183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05032183, "Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05032183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*